The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immunotherapy for Neuroblastoma Market Research Report 2024

Global Immunotherapy for Neuroblastoma Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1743059

No of Pages : 87

Ask Your Query

Synopsis
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

Global Immunotherapy for Neuroblastoma market is projected to reach US$ 63 million in 2029, increasing from US$ 45 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Immunotherapy for Neuroblastoma market research.

Key companies engaged in the Immunotherapy for Neuroblastoma industry include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Immunotherapy for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Immunotherapy for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Immunotherapy for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • United Therapeutics
  • Y-mAbs Therapeutics
  • EUSA Pharma
  • ANI Pharmaceuticals
  • Baxter Healthcare
  • Ingenus Pharmaceuticals
  • Pfizer
  • Hikma Pharmaceuticals
  • Teva Pharmaceuticals

Segment by Type

  • Dinutuximab
  • Naxitamab
  • Other

Segment by Application

  • Hospital
  • Clinic
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Immunotherapy for Neuroblastoma report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

List of Tables
Table 1. Global Immunotherapy for Neuroblastoma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Dinutuximab
Table 3. Key Players of Naxitamab
Table 4. Key Players of Other
Table 5. Global Immunotherapy for Neuroblastoma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Immunotherapy for Neuroblastoma Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Immunotherapy for Neuroblastoma Market Share by Region (2018-2023)
Table 9. Global Immunotherapy for Neuroblastoma Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Immunotherapy for Neuroblastoma Market Share by Region (2024-2029)
Table 11. Immunotherapy for Neuroblastoma Market Trends
Table 12. Immunotherapy for Neuroblastoma Market Drivers
Table 13. Immunotherapy for Neuroblastoma Market Challenges
Table 14. Immunotherapy for Neuroblastoma Market Restraints
Table 15. Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Immunotherapy for Neuroblastoma Market Share by Players (2018-2023)
Table 17. Global Top Immunotherapy for Neuroblastoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy for Neuroblastoma as of 2022)
Table 18. Ranking of Global Top Immunotherapy for Neuroblastoma Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Immunotherapy for Neuroblastoma Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Immunotherapy for Neuroblastoma Product Solution and Service
Table 22. Date of Enter into Immunotherapy for Neuroblastoma Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Immunotherapy for Neuroblastoma Revenue Market Share by Type (2018-2023)
Table 26. Global Immunotherapy for Neuroblastoma Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Immunotherapy for Neuroblastoma Revenue Market Share by Type (2024-2029)
Table 28. Global Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Immunotherapy for Neuroblastoma Revenue Market Share by Application (2018-2023)
Table 30. Global Immunotherapy for Neuroblastoma Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Immunotherapy for Neuroblastoma Revenue Market Share by Application (2024-2029)
Table 32. North America Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Immunotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Immunotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Immunotherapy for Neuroblastoma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Immunotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country (2024-2029) & (US$ Million)
Table 47. United Therapeutics Company Detail
Table 48. United Therapeutics Business Overview
Table 49. United Therapeutics Immunotherapy for Neuroblastoma Product
Table 50. United Therapeutics Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 51. United Therapeutics Recent Development
Table 52. Y-mAbs Therapeutics Company Detail
Table 53. Y-mAbs Therapeutics Business Overview
Table 54. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product
Table 55. Y-mAbs Therapeutics Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 56. Y-mAbs Therapeutics Recent Development
Table 57. EUSA Pharma Company Detail
Table 58. EUSA Pharma Business Overview
Table 59. EUSA Pharma Immunotherapy for Neuroblastoma Product
Table 60. EUSA Pharma Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 61. EUSA Pharma Recent Development
Table 62. ANI Pharmaceuticals Company Detail
Table 63. ANI Pharmaceuticals Business Overview
Table 64. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product
Table 65. ANI Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 66. ANI Pharmaceuticals Recent Development
Table 67. Baxter Healthcare Company Detail
Table 68. Baxter Healthcare Business Overview
Table 69. Baxter Healthcare Immunotherapy for Neuroblastoma Product
Table 70. Baxter Healthcare Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 71. Baxter Healthcare Recent Development
Table 72. Ingenus Pharmaceuticals Company Detail
Table 73. Ingenus Pharmaceuticals Business Overview
Table 74. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product
Table 75. Ingenus Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 76. Ingenus Pharmaceuticals Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Immunotherapy for Neuroblastoma Product
Table 80. Pfizer Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Hikma Pharmaceuticals Company Detail
Table 83. Hikma Pharmaceuticals Business Overview
Table 84. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product
Table 85. Hikma Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 86. Hikma Pharmaceuticals Recent Development
Table 87. Teva Pharmaceuticals Company Detail
Table 88. Teva Pharmaceuticals Business Overview
Table 89. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product
Table 90. Teva Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2018-2023) & (US$ Million)
Table 91. Teva Pharmaceuticals Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immunotherapy for Neuroblastoma Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Immunotherapy for Neuroblastoma Market Share by Type: 2022 VS 2029
Figure 3. Dinutuximab Features
Figure 4. Naxitamab Features
Figure 5. Other Features
Figure 6. Global Immunotherapy for Neuroblastoma Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Immunotherapy for Neuroblastoma Market Share by Application: 2022 VS 2029
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Other Case Studies
Figure 11. Immunotherapy for Neuroblastoma Report Years Considered
Figure 12. Global Immunotherapy for Neuroblastoma Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Immunotherapy for Neuroblastoma Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Immunotherapy for Neuroblastoma Market Share by Region: 2022 VS 2029
Figure 15. Global Immunotherapy for Neuroblastoma Market Share by Players in 2022
Figure 16. Global Top Immunotherapy for Neuroblastoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy for Neuroblastoma as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Immunotherapy for Neuroblastoma Revenue in 2022
Figure 18. North America Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Immunotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 20. United States Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Immunotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 24. Germany Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Immunotherapy for Neuroblastoma Market Share by Region (2018-2029)
Figure 32. China Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Immunotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 40. Mexico Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Immunotherapy for Neuroblastoma Market Share by Country (2018-2029)
Figure 44. Turkey Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Immunotherapy for Neuroblastoma Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. United Therapeutics Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 47. Y-mAbs Therapeutics Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 48. EUSA Pharma Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 49. ANI Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 50. Baxter Healthcare Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 51. Ingenus Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 53. Hikma Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 54. Teva Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock